IN THE SPOTLIGHT MET Receptor Juxtamembrane Exon 14 Alternative Spliced Variant: Novel Cancer Genomic Predictive Biomarker
نویسندگان
چکیده
802 | CANCER DISCOVERY AUGUST 2015 www.aacrjournals.org 1 Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, West Virginia. 2 West Virginia Clinical and Translational Science Institute, Morgantown, West Virginia. Corresponding Author: Patrick C. Ma, West Virginia University, One Medical Center Drive, P.O. Box 9300, Morgantown, WV 26506. Phone: 304-2934229, ext. 2; Fax: 304-293-4667; E-mail: [email protected] doi: 10.1158/2159-8290.CD-15-0769 ©2015 American Association for Cancer Research. IN THE SPOTLIGHT MET Receptor Juxtamembrane Exon 14 Alternative Spliced Variant: Novel Cancer Genomic Predictive Biomarker Patrick C. Ma 1,2
منابع مشابه
MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.
Clinical studies on MET-targeting cancer therapeutics have yielded mixed results in recent years, and MET-relevant predictive biomarkers remain elusive. New studies now reveal METex14 alternative splicing aberrations to represent potential predictive cancer genomic biomarker, hence renewing optimism and directions in the quest for optimized MET-targeting personalized cancer therapy.
متن کاملComprehensive exon array data processing method for quantitative analysis of alternative spliced variants
Alternative splicing of pre-mRNA generates protein diversity. Dysfunction of splicing machinery and expression of specific transcripts has been linked to cancer progression and drug response. Exon microarray technology enables genome-wide quantification of expression levels of the majority of exons and facilitates the discovery of alternative splicing events. Analysis of exon array data is more...
متن کاملCorrection: Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping.
UNLABELLED Mutations in the MET exon 14 RNA splice acceptor and donor sites, which lead to exon skipping, deletion of the juxtamembrane domain containing the CBL E3-ubiquitin ligase-binding site, and decreased turnover of the resultant aberrant MET protein, were previously reported to be oncogenic in preclinical models. We now report responses to the MET inhibitors crizotinib and cabozantinib i...
متن کاملMET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering
The receptor tyrosine kinase MET and its ligand, the hepatocyte growth factor, are essential to embryonic development, whereas deregulation of MET signaling is associated with tumorigenesis leading to various cancers, including lung carcinoma. Mutations in the MET kinase domain lead to constitutive kinase activity and are associated with tumorigenesis. In lung cancer, however, some mutations ar...
متن کاملc-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer
BACKGROUND c-Met mutations play a critical role in the development and progression of primary tumors and metastases. Activation of the HGF/SF-c-Met pathway determines a poor prognosis in non-small-cell and small-cell lung cancer (SCLC) patients. Missense mutations of c-Met have been identified in SCLC patients located in the juxtamembrane (JM) and in the Sema domain. To determine the role of th...
متن کامل